ε-sarcoglycan immunoreactivity and mRNA expression in mouse brain

Journal of Comparative Neurology

Volumn 482, Issue 1, 2005, Pages 50-73

  Chan, Pokman ^a   Gonzalez Maeso, Javier ^a   Ruf, Frédérique ^a   Bishop, David F ^a   Hof, Patrick R ^a   Sealfon, Stuart C ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Dopamine; Dystonia; Fluorescence in situ hybridization; Myoclonus; Obsessive compulsive disorder; Panic attacks; Quantum dot; Serotonin

Indexed keywords

EPSILON SARCOGLYCAN; MESSENGER RNA; SARCOGLYCAN; TRYPTOPHAN HYDROXYLASE; UNCLASSIFIED DRUG; BIOGENIC AMINE; DOPAMINE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; CEREBELLUM; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; DYSTONIA; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC DISORDER; GENOME IMPRINTING; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MENTAL DISEASE; MONOAMINE RELEASE; MOUSE; MYOCLONUS; NEUROANATOMY; NONHUMAN; OLFACTORY BULB; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PURKINJE CELL; RNA ANALYSIS; SYMPTOMATOLOGY; ANIMAL; BRAIN; CYTOLOGY; GENETICS; MESENCEPHALON; METABOLISM; NERVE CELL; TISSUE DISTRIBUTION;

ANIMALS; BIOGENIC MONOAMINES; BRAIN; DOPAMINE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MESENCEPHALON; MICE; NEURONS; OLFACTORY BULB; PURKINJE CELLS; RNA, MESSENGER; SARCOGLYCANS; TISSUE DISTRIBUTION;

EID: 11244345193     PISSN: 00219967     EISSN: None     Source Type: Journal    
DOI: 10.1002/cne.20377     Document Type: Article

References (47)

1. Asmus F, Zimprich A, Naumann M, Berg D, Bertram M, Ceballos-Baumann A, Pruszak-Seel R, Kabus C, Dichgans M, Fuchs S, Muller-Myhsok B, Gasser T. 2001. Inherited myoclonus-dystonia syndrome: narrowing the 7q21-q31 locus in German families. Ann Neurol 49:121-124.
2. Asmus F, Zimprich A, Tezenas Du Montcel S, Kabus C, Deuschl G, Kupsch A, Ziemann U, Castro M, Kuhn AA, Strom TM, Vidailhet M, Bhatia KP, Durr A, Wood NW, Brice A, Gasser T. 2002. Myoclonus-dystonia syndrome: epsilon-sarcoglycan mutations and phenotype. Ann Neurol 52:489-492.
3. Bandmann O, Vaughan J, Holmans PA, Marsden CD, Wood NW. 1999. Toxins, genetics, and Parkinson's disease: the role of N-acetyltransferase 2. Adv Neurol 80:199-204.
4. Chou-Green JM, Holscher TD, Dallman MF, Akana SF. 2003. Compulsive behavior in the 5-HT2C receptor knockout mouse. Physiol Behav 78:641-649.
5. Dickens NJ, Beatson S, Ponting CP. 2002. Cadherin-like domains in alpha-dystroglycan, alpha/epsilon-sarcoglycan and yeast and bacterial proteins. Curr Biol 12:R197-199.
6. dos Santos MR, Jorge P, Ribeiro EM, Pires MM, Guimaraes A. 1998. Noval mutation (Y184C) in exon 4 of the beta-sarcoglycan gene identified in a Portuguese patient. Mutations in brief no. 177. Online. Hum Mutat 12:214-215.
7. Ettinger AJ, Feng G, Sanes JR. 1997. ε-Sarcoglycan, a broadly expressed homologue of the gene mutated in limb-girdle muscular dystrophy 2D. J Biol Chem 272:32534-32538.
8. Ettinger AJ, Feng G, Sanes JR. 1998. ε-Sarcoglycan, a broadly expressed homologue of the gene mutated in limbic-girdle muscular dystrophy 2D. J Biol Chem 272:32534-32538. Erratum in: J Biol Chem 273: 19922.
9. Ettinger AJ, Feng G, Sanes JR. 1998. ε-Sarcoglycan, a broadly expressed homologue of the gene mutated in limbic-girdle muscular dystrophy 2D. J Biol Chem 272:32534-32538. Erratum in: J Biol Chem 273: 19922.
10. Fanin M, Duggan DJ, Mostacciuolo ML, Martinello F, Freda MP, Soraru G, Trevisan CP, Hoffman EP, Angelini C. 1997. Genetic epidemiology of muscular dystrophies resulting from sarcoglycan gene mutations. J Med Genet 34:973-977.
11. Femino AM, Fogarty K, Lifshitz LM, Carrington W, Singer RH. 2003. Visualization of single molecules of mRNA in situ. Methods Enzymol 361:245-304.
12. Fishell G, Mason CA, Hatten ME. 1993. Dispersion of neural progenitors within the germinal zones of the forebrain. Nature 362:636-638.
13. Grabowski M, Zimprich A, Lorenz-Depiereux B, Kalscheuer V, Asmus F, Gasser T, Meitinger T, Strom TM. 2003. The epsilon-sarcoglycan gene (SGCE), mutated in myoclonus-dystonia syndrome, is maternally imprinted. Eur J Hum Genet 11:138-144.
14. Groisman I, Huang YS, Mendez R, Cao Q, Theurkauf W, Richter JD. 2000. CPEB, maskin, and cyclin B1 mRNA at the mitotic apparatus: implications for local translational control of cell division. Cell 103:435-447.
15. Hof PR, Young WG, Bloom FE, Belichenko PV, Celio MR. 2000. Comparative cytoarchitectonic atlas of the C57BL/6 and 129/Sv mouse brains. Amsterdam: Elsevier.
16. Holt KH, Campbell KP. 1998. Assembly of the sarcoglycan complex. Insights for muscular dystrophy. J Biol Chem 273:34667-34670.
17. Inoue T, Tanaka T, Takeichi M, Chisaka O, Nakamura S, Osumi N. 2001. Role of cadherins in maintaining the compartment boundary between the cortex and striatum during development. Development 128:561-569.
18. Klein C. 2003. In Pulst SM, editor. Genetics of movement disorders. Amsterdam: Elsevier Science. Myoclonus and myoclonus-dystonias. p 451-471.
19. Klein C, Brin MF, Kramer P, Sena-Esteves M, de Leon D, Doheny D, Bressman S, Fahn S, Breakefield XO, Ozelius LJ. 1999. Association of a missense change in the D2 dopamine receptor with myoclonus dystonia. Proc Natl Acad Sci U S A 96:5173-5176.
20. Klein C, Gurvich N, Sena-Esteves M, Bressman S, Brin MF, Ebersole BJ, Fink S, Forsgren L, Friedman J, Grimes D, Holmgren G, Kyllerman M, Lang AE, de Leon D, Leung J, Prioleau C, Raymond D, Sanner G, Saunders-Pullman R, Vieregge P, Wahlstrom J, Breakefield XO, Kramer PL, Ozelius LJ, Sealfon SC. 2000a. Evaluation of the role of the D2 dopamine receptor in myoclonus dystonia. Ann Neurol 47:369-373.
21. Klein C, Schilling K, Saunders-Pullman RJ, Garrels J, Breakefield XO, Brin MF, de Leon D, Doheny D, Fahn S, Fink JS, Forsgren L, Friedman J, Frucht S, Harris J, Holmgren G, Kis B, Kurlan R, Kyllerman M, Lang AE, Leung J, Raymond D, Robishaw JD, Sanner G, Schwinger E, Tabamo RE, Tagliati M. 2000b. A major locus for myoclonus-dystonia maps to chromosome 7q in eight families. Am J Hum Genet 67:1314-1319.
22. Klein C, Liu L, Doheny D, Kock N, Muller B, de Carvalho Aguiar P, Leung J, de Leon D, Bressman SB, Silverman J, Smith C, Danisi F, Morrison C, Walker RH, Velickovic M, Schwinger E, Kramer PL, Breakefield XO, Brin MF, Ozelius LJ. 2002. Epsilon-sarcoglycan mutations found in combination with other dystonia gene mutations. Ann Neurol 52:675-679.
23. Kloc M, Zearfoss NR, Etkin LD. 2002. Mechanisms of subcellular mRNA localization. Cell 108:533-544.
24. Knappskog PM, Flatmark T, Mallet J, Ludecke B, Bartholome K. 1995. Recessively inherited L-DOPA-responsive dystonia caused by a point mutation (Q381K) in the tyrosine hydroxylase gene. Hum Mol Genet 4:1209-1212.
25. Lim LE, Campbell KP. 1998. The sarcoglycan complex in limb-girdle muscular dystrophy. Curr Opin Neurol 11:443-452.
26. Lin S, Ramelli GP, Moser H, Gallati S, Burgunder JM. 2002. A novel insert mutation in gamma-sarcoglycan gene leads to severe childhood autosomal recessive muscular dystrophy. J Neurol 249:1608-1611.
27. Marechal L, Raux G, Dumanchin C, Lefebvre G, Deslandre E, Girard C, Campion D, Parain D, Frebourg T, Hannequin D. 2003. Severe myoclonus-dystonia syndrome associated with a novel epsilon-sarcoglycan gene truncating mutation. Am J Med Genet 119B:114-117.
28. McNally EM, Duggan D, Gorospe JR, Bonnemann CG, Fanin M, Pegoraro E, Lidov HG, Noguchi S, Ozawa E, Finkel RS, Cruse RP, Angelini C, Kunkel LM, Hoffman EP. 1996. Mutations that disrupt the carboxyl-terminus of gamma-sarcoglycan cause muscular dystrophy. Hum Mol Genet 5:1841-1847.
29. McNally EM, Ly CT, Kunkel LM. 1998. Human epsilon-sarcoglycan is highly related to alpha-sarcoglycan (adhalin), the limb girdle muscular dystrophy 2D gene. FEES Lett 422:27-32.
30. Michele DE, Barresi R, Kanagawa M, Saito F, Cohn RD, Satz JS, Dollar J, Nishino I, Kelley RI, Somer H, Straub V, Mathews KD, Moore SA, Campbell KP. 2002. Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. Nature 418:417-422.
31. Muller B, Hedrich K, Kock N, Dragasevic N, Svetel M, Garrels J, Landt O, Nitschke M, Pramstaller PP, Reik W, Schwinger E, Sperner J, Ozelius L, Kostic V, Klein C. 2002. Evidence that paternal expression of the epsilon-sarcoglycan gene accounts for reduced penetrance in myoclonus-dystonia. Am J Hum Genet 71:1303-1311.
32. Noguchi S, McNally EM, Ben Othmane K, Hagiwara Y, Mizuno Y, Yoshida M, Yamamoto H, Bonnemann CG, Gussoni E, Denton PH, Kyriakides T, Middleton L, Hentati F, Ben Hamida M, Nonaka I, Vance JM, Kunkel LM, Ozawa E. 1995. Mutations in the dystrophin-associated protein gamma-sarcoglycan in chromosome 13 muscular dystrophy. Science 270:819-822.
33. Nygaard TG, Raymond D, Chen C, Nishino I, Greene PE, Jennings D, Heiman GA, Klein C, Saunders-Pullman RJ, Kramer P, Ozelius LJ, Bressman SB. 1999. Localization of a gene for myoclonus-dystonia to chromosome 7q21-q31. Ann Neurol 46:794-798.
34. Roberds SL, Leturcq F, Allemand V, Piccolo F, Jeanpierre M, Anderson RD, Lim LE, Lee JC, Tome FM, Romero NB, Fardeau M, Beckmann JC, Kaplan J, Campbell KP. 1994. Missense mutations in the adhalin gene linked to autosomal recessive muscular dystrophy. Cell 78:625-633.
35. Robinson R, McCarthy GT, Bandmann O, Dobbie M, Surtees R, Wood NW. 1999. GTP cyclohydrolase deficiency; intrafamilial variation in clinical phenotype, including levodopa responsiveness. J Neurol Neurosurg Psychiatry 66:86-89.
36. Saunders-Pullman R, Shriberg J, Heiman G, Raymond D, Wendt K, Kramer P, Schilling K, Kurlan R, Klein C, Ozelius LJ, Risch NJ, Bressman SB. 2002. Myoclonus dystonia: possible association with obsessive-compulsive disorder and alcohol dependence. Neurology 58:242-245.
37. Sealfon SC, Olanow CW. 2000. Dopamine receptors: from structure to behavior. Trends Neurosci 23(10 suppl):S34-40.
38. Sheth U, Parker R. 2003. Decapping and decay of messenger RNA occur in cytoplasmic processing bodies. Science 300:805-808.
39. Straub V, Duclos F, Venzke DP, Lee JC, Cutshall S, Leveille CJ, Campbell KP. 1998. Molecular pathogenesis of muscle degeneration in the δ-sarcoglycan-deficient hamster. Am J Pathol 153:1623-1630.
40. Takeichi M, Matsunami H, Inoue T, Kimura Y, Suzuki S, Tanaka T. 1997. Roles of cadherins in patterning of the developing brain. Dev Neurosci 19:86-87.
41. Tepass U, Truong K, Godt D, Ikura M, Peifer M. 2000. Cadherins in embryonic and neuralmorphogenesis. Nat Rev Mol Cell Biol 1:91-100.
42. Thoren P, Asberg M, Bertilsson L, Mellstrom B, Sjoqvist F, Traskman L. 1980. Clomipramine treatment of obsessive-compulsive disorder. II. Biochemical aspects. Arch Gen Psychiatry 37:1289-1294.
43. Vidailhet M, Tassin J, Durif F, Nivelon-Chevallier A, Agid Y, Brice A, Durr A. 2001. A major locus for several phenotypes of myoclonus-dystonia on chromosome 7q. Neurology 56:1213-1216.
44. Wheeler MT, Zarnegar S, McNally EM. 2002. Zeta-sarcoglycan, a novel component of the sarcoglycan complex, is reduced in muscular dystrophy. Hum Mol Genet 11:2147-2154.
45. Wickens M, Goldstrohm A. 2003. Molecular biology. A place to die, a place to sleep. Science 300:753-755.
46. Xiao J, LeDoux MS. 2003. Cloning, developmental regulation and neural localization of rat epsilon-sarcoglycan. Mol Brain Res 119:132-43.
47. Zimprich A, Grabowski M, Asmus F, Naumann M, Berg D, Bertram M, Scheidtmann K, Kern P, Winkelmann J, Muller-Myhsok B, Riedel L, Bauer M, Muller T, Castro M, Meitinger T, Strom TM, Gasser T. 2001. Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome. Nat Genet 29:66-69.